News

Public · Published

Kodiak Sciences Reports Q3 2026 Net Loss of $66.2 Million, $88.7 Million in Cash

Kodiak Sciences reported a third-quarter 2026 net loss of $66.2 million, or $1.05 per share, compared with a $61.5 million loss a year earlier. Research and development spending rose to $58.3 million, and cash was $88.7 million at quarter-end. After the quarter, it raised $69 million through an at-the-market share offering.

Published:

Updated:

What happened

Kodiak Sciences reported a third-quarter 2026 net loss of $66.2 million, or $1.05 per share, compared with a $61.5 million loss a year earlier. Research and development spending rose to $58.3 million, and cash was $88.7 million at quarter-end. After the quarter, it raised $69 million through an at-the-market share offering.

Confirmed

Global impact / market context

The larger quarterly loss and rising research spending show that developing treatments is consuming substantial cash. The $69 million share sale added funds after quarter-end, but issuing shares can dilute existing ownership; investors will weigh that funding against the company’s reported cash and future spending needs.

Analyst inference

Kodiak’s report combines financial pressure with a positive study result: Zenkuda met its Phase 3 DAYBREAK primary endpoint, the main measure the trial was designed to test. That result and the planned fourth-quarter 2026 regulatory submission may shape expectations, but neither establishes approval or future sales.

Analyst inference

What to watch

  1. Watch whether Kodiak submits the planned multi-indication Zenkuda application in the fourth quarter of 2026, as stated, and what the filing says about its scope. Proposed
  2. Track cash and spending in upcoming reports: research and development costs rose year over year, while the $69 million share sale provided additional funds after quarter-end. Analyst inference
  3. Follow any further details on DAYBREAK’s results and reported safety, since the company said the trial met its main endpoint and safety matched aflibercept’s established profile. Analyst inference

Evidence

  • Original source link unavailable